DBV Technologies (NASDAQ:DBVT) Stock Price Down 9.1% – Time to Sell?

DBV Technologies S.A. (NASDAQ:DBVT) shares fell 9.1% on Monday . The company traded as low as $17.49 and last traded at $17.3150. 71,626 shares were traded during trading, a decline of 66% from the average session volume of 207,616 shares. The stock had previously closed at $19.05.

Analysts Set New Price Targets

DBVT has been the subject of several research analyst reports. Wall Street Zen upgraded shares of DBV Technologies from a “sell” rating to a “hold” rating in a report on Friday, November 28th. Citigroup reissued an “outperform” rating on shares of DBV Technologies in a research report on Wednesday, December 17th. Guggenheim restated a “buy” rating and issued a $51.00 target price (up previously from $35.00) on shares of DBV Technologies in a research note on Wednesday, December 17th. HC Wainwright set a $40.00 price target on DBV Technologies in a research note on Thursday, December 18th. Finally, Zacks Research upgraded DBV Technologies from a “strong sell” rating to a “hold” rating in a report on Monday, September 29th. Two investment analysts have rated the stock with a Strong Buy rating, five have given a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $35.38.

DBV Technologies Stock Performance

The firm has a 50-day moving average of $16.14 and a 200-day moving average of $12.73. The firm has a market capitalization of $722.48 million, a P/E ratio of -3.48 and a beta of -1.17.

Insider Activity at DBV Technologies

In related news, major shareholder Bpifrance Epic sold 1,292,103 shares of DBV Technologies stock in a transaction dated Thursday, December 18th. The stock was sold at an average price of $4.19, for a total value of $5,413,911.57. Following the completion of the sale, the insider directly owned 7,303,369 shares in the company, valued at approximately $30,601,116.11. This trade represents a 15.03% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 1.44% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the stock. GAMMA Investing LLC boosted its holdings in DBV Technologies by 38.4% in the fourth quarter. GAMMA Investing LLC now owns 2,680 shares of the company’s stock worth $51,000 after purchasing an additional 744 shares during the last quarter. New York State Common Retirement Fund bought a new position in shares of DBV Technologies during the 3rd quarter valued at $34,000. Two Sigma Investments LP bought a new position in shares of DBV Technologies during the 3rd quarter valued at $167,000. Citadel Advisors LLC purchased a new position in shares of DBV Technologies in the 3rd quarter worth $220,000. Finally, DLD Asset Management LP bought a new stake in shares of DBV Technologies in the third quarter worth $250,000. 71.74% of the stock is owned by hedge funds and other institutional investors.

DBV Technologies Company Profile

DBV Technologies SA is a clinical-stage biopharmaceutical company engaged in developing immunotherapies for allergic diseases. The company specializes in epicutaneous immunotherapy, leveraging its proprietary Viaskin platform to deliver biologically active compounds across intact skin without needles or injections. Through this approach, DBV aims to modulate patients’ immune response to specific allergens, offering a potentially safer and more convenient alternative to traditional therapies.

The company’s lead product candidate, Viaskin Peanut, is designed for the treatment of peanut allergy in children and adolescents.